Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

mehr ...

erschienen in

mehr ...

Verlag

mehr ...

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 34, Suchdauer: 0.72s

12 weiter »

1
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.

von Lincoff AM ; Nicholls SJ ; Riesmeyer JS ; et al.

Schlagworte: Evacetrapib; cholesteryl ester transfer protein inhibitor; Cardiovascular Outcome; High-Risk Vascular Disease
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

2
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

von Wun, T ; Soulieres, D ; Frelinger, AL ; et al.
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

3
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

4
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

5
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

6
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

7
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

8

Dieses Ergebnis aus CINAHL kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.

Merkliste

9
Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.

von McGuire DK ; D'Alessio D ; Nicholls SJ ; et al.

Cardiovascular diabetology [Cardiovasc Diabetol] 2022 Aug 24; Vol. 21 (1), pp. 163. Date of Electronic Publication: 2022 Aug 24.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

10
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

von Del Prato S ; Kahn SE ; Pavo I ; et al.

Lancet (London, England) [Lancet] 2021 Nov 13; Vol. 398 (10313), pp. 1811-1824. Date of Electronic Publication: 2021 Oct 18.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

11
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.

von Wilson JM ; Nikooienejad A ; Robins DA ; et al.

Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Dec; Vol. 22 (12), pp. 2451-2459. Date of Electronic Publication: 2020 Sep 15.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

12
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.

von Puri R ; Nissen SE ; Arsenault BJ ; et al.

JAMA cardiology [JAMA Cardiol] 2020 Oct 01; Vol. 5 (10), pp. 1136-1143.
- Volltextverfügbarkeit prüfen (via ReDI)
- Zur Referenz in PubMed
Merkliste

13
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.

von Sharma A ; Pagidipati NJ ; Califf RM ; et al.

Circulation [Circulation] 2020 Mar 10; Vol. 141 (10), pp. 843-862. Date of Electronic Publication: 2020 Jan 29.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

14
Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.

von Emdin CA ; Bhatnagar P ; Wang M ; et al.

Circulation. Genomic and precision medicine [Circ Genom Precis Med] 2020 Feb; Vol. 13 (1), pp. e002767. Date of Electronic Publication: 2020 Jan 03.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

15
The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE.

von Shah NP ; Wang Q ; Wolski KE ; et al.

Diabetes care [Diabetes Care] 2020 Feb; Vol. 43 (2), pp. e22-e24. Date of Electronic Publication: 2019 Dec 05.
- Volltextverfügbarkeit prüfen (via ReDI)
- Zur Referenz in PubMed
Merkliste

16
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.

von Menon V ; Kumar A ; Patel DR ; et al.

Journal of the American Heart Association [J Am Heart Assoc] 2020 Jan 07; Vol. 9 (1), pp. e014328. Date of Electronic Publication: 2019 Dec 19.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

17
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial.

von Kumar A ; Patel DR ; Brennan DM ; et al.

Journal of the American Heart Association [J Am Heart Assoc] 2019 Dec 03; Vol. 8 (23), pp. e013790. Date of Electronic Publication: 2019 Nov 22.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

18
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

von Gerstein HC ; Colhoun HM ; Dagenais GR ; et al.

Lancet (London, England) [Lancet] 2019 Jul 13; Vol. 394 (10193), pp. 121-130. Date of Electronic Publication: 2019 Jun 09.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

19
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.

von Boye KS ; Riddle MC ; Gerstein HC ; et al.

Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Jun; Vol. 21 (6), pp. 1299-1304. Date of Electronic Publication: 2019 Mar 12.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

20
Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial.

von Kumar A ; Patel DR ; Wolski KE ; et al.

Diabetes & vascular disease research [Diab Vasc Dis Res] 2019 Mar; Vol. 16 (2), pp. 171-177.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

21
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.

von Nissen SE ; Pillai SG ; Nicholls SJ ; et al.

JAMA cardiology [JAMA Cardiol] 2018 May 01; Vol. 3 (5), pp. 401-408.
- Volltextverfügbarkeit prüfen (via ReDI)
- Zur Referenz in PubMed
Merkliste

22
Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia.

von Teramoto T ; Kiyosue A ; Iimura T ; et al.

Circulation journal : official journal of the Japanese Circulation Society [Circ J] 2017 Dec 25; Vol. 82 (1), pp. 183-191. Date of Electronic Publication: 2017 Aug 03.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

23
Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia.

von Teramoto T ; Kiyosue A ; Iimura T ; et al.

Circulation journal : official journal of the Japanese Circulation Society [Circ J] 2017 Oct 25; Vol. 81 (11), pp. 1686-1692. Date of Electronic Publication: 2017 Jun 23.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

24
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.

von Nicholls SJ ; Ray KK ; Ballantyne CM ; et al.

Atherosclerosis [Atherosclerosis] 2017 Jun; Vol. 261, pp. 12-18. Date of Electronic Publication: 2017 Apr 08.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

25
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.

von Wun T ; Soulieres D ; Frelinger AL ; et al.

Journal of hematology & oncology [J Hematol Oncol] 2013 Feb 17; Vol. 6, pp. 17. Date of Electronic Publication: 2013 Feb 17.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

12 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag